NANTBIO Trademark

Trademark Overview

On Friday, January 6, 2017, a trademark application was filed for NANTBIO with the United States Patent and Trademark Office. The USPTO has given the NANTBIO trademark a serial number of 87292134. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 15, 2021. This trademark is owned by Nant Holdings IP, LLC. The NANTBIO trademark is filed in the Pharmaceutical Products category with the following description:

Cell-derived preparations for clinical, medicinal, therapeutic, and medical diagnostic purposes; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for immunotherapy treatment; Pharmaceutical preparations derived from monoclonal antibodies for the treatment of cancer; Pharmaceutical preparations, namely, epitope mapping systems, composed of antibodies, for use in the diagnosis and treatment of cancer; Pharmaceutical preparations for the treatment of allograft rejection; Therapeutic antibodies and immune system modulators, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations, namely, small molecule therapies for treating cancer; Vaccines
nantbio

General Information

Serial Number87292134
Word MarkNANTBIO
Filing DateFriday, January 6, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 15, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2017

Trademark Statements

Goods and ServicesCell-derived preparations for clinical, medicinal, therapeutic, and medical diagnostic purposes; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for immunotherapy treatment; Pharmaceutical preparations derived from monoclonal antibodies for the treatment of cancer; Pharmaceutical preparations, namely, epitope mapping systems, composed of antibodies, for use in the diagnosis and treatment of cancer; Pharmaceutical preparations for the treatment of allograft rejection; Therapeutic antibodies and immune system modulators, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations, namely, small molecule therapies for treating cancer; Vaccines
Pseudo MarkNANT BIO

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 13, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNant Holdings IP, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCulver City, CA 90232
Party NameNant Holdings IP, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCulver City, CA 90232

Trademark Events

Event DateEvent Description
Tuesday, February 16, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 15, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 5, 2020EXTENSION 5 GRANTED
Thursday, July 9, 2020EXTENSION 5 FILED
Wednesday, August 5, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, July 9, 2020TEAS EXTENSION RECEIVED
Friday, January 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 8, 2020EXTENSION 4 GRANTED
Wednesday, January 8, 2020EXTENSION 4 FILED
Wednesday, January 8, 2020TEAS EXTENSION RECEIVED
Thursday, July 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 9, 2019EXTENSION 3 GRANTED
Tuesday, July 9, 2019EXTENSION 3 FILED
Tuesday, July 9, 2019TEAS EXTENSION RECEIVED
Friday, January 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 9, 2019EXTENSION 2 GRANTED
Wednesday, January 9, 2019EXTENSION 2 FILED
Wednesday, January 9, 2019TEAS EXTENSION RECEIVED
Saturday, July 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 5, 2018EXTENSION 1 GRANTED
Thursday, July 5, 2018EXTENSION 1 FILED
Thursday, July 5, 2018TEAS EXTENSION RECEIVED
Tuesday, January 9, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 14, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 14, 2017PUBLISHED FOR OPPOSITION
Wednesday, October 25, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 9, 2017ASSIGNED TO LIE
Monday, September 25, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, September 23, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 22, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 22, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 7, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 7, 2017NON-FINAL ACTION E-MAILED
Friday, April 7, 2017NON-FINAL ACTION WRITTEN
Thursday, March 30, 2017ASSIGNED TO EXAMINER
Saturday, January 14, 2017NOTICE OF PSEUDO MARK E-MAILED
Friday, January 13, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, January 10, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

nantbio preparations pharmaceutical treatment cancer namely antibodies derived therapeutic immune diagnosis